Yoshitaka Arase Selected Research

Yoshitaka Arase Research Topics

Disease

10	Hepatocellular Carcinoma (Hepatoma) 03/2024 - 05/2012
5	Liver Cirrhosis (Hepatic Cirrhosis) 01/2023 - 02/2015
3	Fibrosis (Cirrhosis) 03/2023 - 02/2015
3	Ascites 03/2023 - 01/2019
3	Body Weight (Weight, Body) 01/2023 - 04/2012
3	End Stage Liver Disease 01/2023 - 01/2020
3	Liver Diseases (Liver Disease) 01/2021 - 12/2018
3	Chronic Hepatitis C 09/2013 - 04/2012
2	Thrombosis (Thrombus) 01/2023 - 02/2014
2	Thrombocytopenia (Thrombopenia) 04/2022 - 01/2021
2	Disease Progression 02/2021 - 11/2016
1	Weight Loss (Weight Reduction) 03/2023
1	Hydrothorax 01/2023
1	Autoimmune Hepatitis 01/2021
1	Hypoalbuminemia 10/2020
1	Hypothyroidism 10/2020
1	Brain Diseases (Brain Disorder) 01/2020
1	Varicose Veins (Varicose Vein) 01/2020
1	Hepatic Encephalopathy 01/2020
1	Rupture 01/2020
1	Osteoporosis 01/2020
1	Esophageal and Gastric Varices (Esophageal Varices) 12/2019
1	Non-alcoholic Fatty Liver Disease 07/2019
1	Type 2 Diabetes Mellitus (MODY) 07/2019
1	Chronic Renal Insufficiency 01/2019
1	Peptic Esophagitis (Reflux Esophagitis) 12/2016
1	Atrophic Gastritis 12/2016
1	Chronic Hepatitis B 03/2016
1	Stomach Neoplasms (Stomach Cancer) 12/2015
1	Hyperbilirubinemia 03/2015
1	Hereditary Hyperbilirubinemia (Rotor Syndrome) 03/2015
1	Neoplasms (Cancer) 09/2014
1	Pancreatitis 02/2014
1	Neutropenia 09/2013
1	Neoplasm Metastasis (Metastasis) 05/2012
1	Lymphatic Metastasis 05/2012
1	Exanthema (Rash) 05/2012
1	Anemia 04/2012

Drug/Important Bio-Agent (IBA)

4	atezolizumabIBA 03/2024 - 03/2022
4	Bevacizumab (Avastin)FDA Link 03/2024 - 03/2022
3	SodiumIBA 01/2023 - 07/2019
3	lusutrombopagIBA 04/2022 - 12/2018
3	Sorafenib (BAY 43-9006)FDA Link 11/2016 - 05/2012
3	Ribavirin (Virazole)FDA LinkGeneric 09/2013 - 04/2012
2	AlbuminsIBA 03/2023 - 01/2020
2	Vasopressin Receptors (Arginine Vasopressin Receptor)IBA 01/2023 - 01/2019
2	Tolvaptan FDA Link 01/2023 - 01/2019
2	Antiviral Agents (Antivirals)IBA 03/2016 - 09/2013
1	ElectrolytesIBA 03/2023
1	Immune Checkpoint InhibitorsIBA 01/2023
1	DiureticsIBA 01/2023
1	Phospholipases (Phospholipase)IBA 01/2022
1	ibrutinibIBA 02/2021
1	Surface Antigens (Surface Antigen)IBA 02/2021
1	Hepatitis B Surface Antigens (HBsAg)FDA Link 02/2021
1	Thrombopoietin (c-mpl Ligand)IBA 01/2021
1	AutoantibodiesIBA 01/2021
1	Immunoglobulins (Immunoglobulin)IBA 01/2021
1	lenvatinibIBA 10/2020
1	BilirubinIBA 01/2020
1	Biomarkers (Surrogate Marker)IBA 01/2020
1	Aspartate Aminotransferases (Aspartate Transaminase)IBA 01/2020
1	Denosumab FDA Link 01/2020
1	Sclerosing Solutions (Sclerosing Agents)IBA 12/2019
1	Glucose (Dextrose)FDA LinkGeneric 07/2019
1	Glycated Hemoglobin (Glycosylated Hemoglobin)IBA 07/2019
1	SymportersIBA 07/2019
1	Clarithromycin (Biaxin)FDA LinkGeneric 12/2016
1	Lansoprazole (Prevacid)FDA LinkGeneric 12/2016
1	Amoxicillin (Wymox)FDA LinkGeneric 12/2016
1	Hepatitis B e AntigensIBA 03/2016
1	NucleosidesIBA 03/2016
1	Peptides (Polypeptides)IBA 03/2015
1	AnionsIBA 03/2015
1	Ethanol (Ethyl Alcohol)IBA 02/2015
1	AcetaldehydeIBA 02/2015
1	Urokinase-Type Plasminogen Activator (Urokinase)FDA Link 02/2014
1	Heparin (Liquaemin)FDA LinkGeneric 02/2014
1	danaparoid (Orgaran)FDA Link 02/2014
1	Meloxicam (Mobic)FDA LinkGeneric 09/2013
1	alpha-Fetoproteins (alpha-Fetoprotein)IBA 05/2012
1	LectinsIBA 05/2012
1	Prothrombin (Factor II)IBA 05/2012
1	InterferonsIBA 05/2012

Therapy/Procedure

13	Therapeutics 03/2023 - 04/2012
2	Duration of Therapy 10/2020 - 09/2014
1	Surgical Portasystemic Shunt (Portosystemic Shunt) 01/2023
1	Transjugular Intrahepatic Portasystemic Shunt 01/2023
1	Thrombolytic Therapy 01/2023
1	Molecular Targeted Therapy 10/2020
1	Glycemic Control 07/2019
1	Stents 02/2014
1	Intravenous Infusions 02/2014
1	Drug Tapering 04/2012